Clinical Trial

Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-09; most recent amendment 2026-02-09.
Trial Details
NCT Number NCT07297563
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Immune Thrombocytopenia, Treatment
Enrollment 160 participants
Start Date 2026-01-20
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-11